Application Research of Video Interaction Service Platform for Hospital Wards / 医疗卫生装备

Objective To modify the way of information-learning for in-ward patients and the modes of living and business services within or out of hospital, thus improving the service acquisitiveness and patient's satisfaction. Methods Based on the integration of the current hospital equipments and internal information, digital service platform was constructed by utilizing all kinds of technologies such as cable television network, broadband local network, internet, multi-media, embedded microcomputer, etc. Results In-ward patient can enjoy video on demand (VOD), bill inquiry, ordering meal, amusement games, business services and external hospital service conveniently via remote control and television in the room. Conclusion The platform introduces the digital technology into non-medical service in hospital. As an innovation in information technology and service pattern, the platform has a future in application.

A Case Study of Constructing a Medical Web-Casting System / 대한의료정보학회지

As digital technologies develop further, computer and communication networks combined more and more. In addition,the integrated systems of broadcasting and communication accelerate the disappearance of business borderline between them.Intemet broadcasting technology such as Video on Demand(VOD) system is a good example. There are also digitized, two-way communication systems such as web-casting, satellite and cable communication networks In order to get better information more effectively in the modern society, the authors needed to actively deal with multimedia contents provided by new media system, such as video-conferencing, distance education, Internet broadcasting, and things go on.This was the way to satisfy customers desire for better services in medical area. Consequently, it became possible to practice telemedicine, including distance medical examination and treatment, counseling, and education. The updated networksystems using ISDN, optical lines, microwaves and multi-channel satellite can be utilized for a video-conferencing system to support an effective telemedicine. In order to establish and execute national information policies effectively, it is requiredthat the laws, regulations, and the organizations related to broadcasting and communication matters need to be modified.The purpose of this paper is to suggest a model of a medical web- casting system with high cost-effectiveness. This has been supported by our experience in establishing an internet broadcasting system at a general hospital.

A Trial Use of Prophylactic Low-Dose Lipo PGE1 (Eglandin) for the Prevention of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation in Children with Hematologic Malignancies / 대한소아혈액종양학회지

PURPOSE: In this study we tested the hypothesis that vasodilatation and antithrombogenic effect in damaged vessels using low-dose Lipo PGE1 might result in increased sinusoidal blood flow and in decreased obstruction and minimize the incidence or severity of hepatic veno-occlusive disease (VOD). METHPDS: Children underwent hematopoietic stem cell transplantation for hematologic malignancies were enrolled in this study. Lipo PGE1 was begun one day prior to the start of conditioning to day 30 after stem cell transplantation in continuous intravenous infusion at a dose of 1 mug/kg/day (0.042 mug/ kg/hr). We evaluate the incidence and severity of hepatic VOD and the toxicity of Lipo PGE1. RESULTS: From November 1999 to Jun 2000, 20 patients (M:F=15:5, median age 5 years) underwent hematopoietic stem cell (5 matched sibling bone marrow, 4 autologous bone marrow, 8 unrelated bone marrow, 3 unrelated cord blood) transplantation for hematologic malignancies (9 ALL, 8 AML, 3 CML) were enrolled in this study. There was no occurrence of VOD within 30 day of transplant. Only one out of 20 patients was diagnosed as delayed VOD, easily controlled moderate form, on post-transplant day 58. There was no toxicity attributed to Lipo PGE1. CONCLUSION: This study suggests that prophylactic low-dose Lipo PGE1 treatment may decrease the incidence of VOD in patients treated for hematologic malignancies by hematopoietic stem cell transplantation.

Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment

Veno-occlusive disease (VOD) of the liver is a clinical syndrome characterized by hyperbilirubinemia, painful hepatomegaly, and fluid retention. In the bone marrow transplantation (BMT) setting, VOD is caused by dose-intensive chemotherapy and/or radiotherapy used to prepare patients for transplant. VOD occurs in up to 50% of the patients who undergo BMT and is usually associated with a high mortality rate. Until recently, there was no proven effective medical therapy for this condition once it was clinically apparent. We report here on the frequency and treatment result of VOD with rt-PA in our allogeneic BMT patients. Eight patients (median age 28.5 years) underwent allogeneic BMT from December, 1993 to June, 1995 in Asan Medical Center. Six leukemia patients were prepared for BMT with busulfan and cyclophosphmide, while two aplastic anemia patients received cyclophosphamide and antithymocyte globulin. VOD was defined as having two of the following features before day 20 posttransplant: jaundice (bilirubin > or = 2 mg/dL), tender hepatomegaly and/or right upper quadrant pain, ascites and/or unexplained weight gain (> 2% from baseline). All patients who were diagnosed with VOD received rt-PA (10-20 mg/day) and heparin (10,000 U/day). Three (37.5%) of the eight patients developed VOD that occurred between 6 and 10 days posttransplant. All three patients developed jaundice, weight gain, and tender hepatomegaly. Ascites and renal insufficiency occurred in two patients and pleural effusion in one patient. rt-PA and heparin were begun 6 to 26 days posttransplant and rt-PA was administered for 7 to 14 days. All three patients responded to the therapy; bilirubin levels began to decrease at 4 to 13 days from the start of therapy. They are all alive at day 111, 316, and 548 days posttransplant. None of the patients had significant hemorrhagic complications after rt-PA treatment. Prolonged administration of rt-PA was feasible without bleeding episode and it seems that rt-PA may alter the natural course of VOD.